A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: Are they protective?

Christina Wolfson, A. Perrault, Y. Moride, J. M. Esdaile, L. Abenhaim, F. Momoli

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

In many studies of nonsteroidal anti-inflammatory drugs (NSAIDs) and Alzheimer's disease (AD), the exposure to NSAIDs was concurrent with AD or based on self (or surrogate) report. We conducted a case-control analysis of the Québec participants in the Canadian Study of Health and Aging who received a diagnosis of AD (cases) or were found to be cognitively unimpaired on screening (controls). Information on drug use was obtained from the Québec Provincial Pharmaceutical Services Database. There was no significant difference in the proportion of cases and controls who had received any NSAID prescriptions in the 3 years prior to the onset of symptoms of dementia; amongst NSAID users, there was no difference in mean dose or duration. Our findings, using a measure of drug use prior to symptom onset and not subject to recall bias, do not support a protective effect for NSAIDs.

Original languageEnglish (US)
Pages (from-to)81-86
Number of pages6
JournalNeuroepidemiology
Volume21
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Clinical Neurology

Keywords

  • Alzheimer's disease
  • Case-control analysis
  • Nonsteroidal anti-inflammatory drugs

Fingerprint

Dive into the research topics of 'A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: Are they protective?'. Together they form a unique fingerprint.

Cite this